Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Transl Stroke Res. 2020 Mar 20;12(1):112–124. doi: 10.1007/s12975-020-00807-y

Fig.6. CD133+Exo treatment significantly decreases cardiac inflammation, increases miR-126 expression and decreases its target genes in T2DM-stroke mice.

Fig.6

CD133+Exo treatment significantly decreases cardiac tissue inflammatory factor expression such as a) transforming growth factor-β (TGF-β), b) M1 macrophage (ED1) and c) monocyte chemoattractant protein 1 (MCP1) compared to PBS treated T2DM-stroke mice. d) CD133+Exo have higher miR-126 expression compared to EC-Exo. e) CD133+Exo treatment significantly increases cardiac miR-126 expression and decreases its target gene Spred-1, VCAM and MCP-1 expression measured using PCR analysis. T2DM-stroke+PBS: n=7; T2DM-stroke+CD133+Exo: n=8.